Neurodome Secures Tens of Millions in Series A Funding to Pioneer Non-Invasive Deep Brain Neuromodulation with Temporal Interference Technology

VCBeat learned第一时间 that recently, Neurodome, Inc. (hereinafter referred to as "Neurodome"), a pioneer in non-invasive deep brain neuromodulation technology, has successfully completed a multi-million yuan Series A round of financing. This round of financing was led byHuafang CapitalAndiFlytek VenturesCo-led by,He Ying CapitalCo-investment,StartPointAdvisorsServed as the exclusive financial advisor for this round of financing.

This round of financing will help the company accelerate the continuous exploration and development of Temporal Interference (TI) technology in the field of brain science, promote multi-scenario product solutions, and advance clinical registration, product certification, and commercialization for various indications.

Neurodome, Inc. always regards clinical needs as the guiding principle, efficiently advancing clinical exploration and industrial implementation based on TI technology. Within just one year of the release of its TI Research Edition product, it has established collaborations with nearly a hundred top clinical centers and university research institutions both domestically and internationally. It has cumulatively conducted over a thousand TI research clinical cases covering dozens of indications, including depression, Parkinson's disease, essential tremor, sleep disorders, post-traumatic stress disorder, and epilepsy, achieving inspiring interim clinical outcomes. Progress is leading globally, providing a new option for non-invasive deep brain neuromodulation in neuroscience and psychiatric disorders.

The field of brain science holds enormous potential for therapeutic demand. In China, the number of patients with various brain diseases is close to 130 million, including over 50 million with depression. The burden caused by brain diseases accounts for 23% of the total disease burden. Current treatment methods have many shortcomings, struggling to balance safety and efficacy. Invasive treatments carry high risks, while non-invasive interventions struggle to achieve both depth and precision. This challenging yet fascinating blue ocean track urgently calls for a new technology leader capable of simultaneously meeting the clinical needs of being non-invasive, deep-brain, precise, and multi-targeted.

Neurodome, Inc. has been deeply engaged in the field of non-invasive neuromodulation for nearly a decade, continuously refining TI technology and being the first to master and achieve precise non-invasive deep-brain neuromodulation using TI in humans. Neurodome’s TI products can accurately output stimulation signals in different modes, finely adjust parameters according to clinical needs, and ensure the accuracy, effectiveness, and repeatability of treatment plans. These products can perfectly achieve non-invasive, deep-brain, high-precision, multi-target central nervous system stimulation interventions and can be widely applied in the treatment of various neurological and psychiatric disorders.

Neurodome, Inc. has established a comprehensive product matrix, achieving full coverage of scenarios from research to clinical settings and from in-hospital to out-of-hospital environments. Its research products have already been commercialized. Recently, Neurodome, Inc. launched new product solutions, TI – TMS and TI-TUS, integrating innovative technologies to provide new tools and technical solutions for clinical research and applications.

In September 2024, the first Global TI Summit, International Meeting on Temporal Interference Brain Stimulation, grandly opened in London. As an industry-leading enterprise, Neurodome showcased its significant breakthroughs in TI technology development, clinical applications, and product innovation to global clinicians and researchers in the TI field. Alongside top neuroscientists, medical experts, and industry leaders, the company discussed the future development of TI technology in the field of neuromodulation.

Marching Forward with Courage, Staying True to the MissionIn the future, Neurodome will continueDriven by innovation,AroundTI TechnologyContinuousIteration, centered on deep brain modulation, initiates coverage of the functional cortex and central regions.-Multi-physical factor regulation product line for the peripheral nervous system, building based onTINeurodome: A Globally Leading Non-Invasive Deep Brain Neuromodulation Platform.

The product on the left is TI's research scenario, and the product on the right is TI's clinical scenario.

New Generation TI-TMS Product Prototype

New Generation TI-TUS Product Prototype

Regarding this round of financing,Dr. Wangqian Luo, Partner of Beijing Huafang Investment Co., Ltd.The brain is the most complex and sophisticated organ in the human body, and research on the human brain has always been one of the ultimate challenges in life sciences. However, non-invasive research methods for the brain are still very limited, let alone functional regulation. Therefore, Beijing Huafang Investment Co., Ltd. has been continuously paying attention to the progress and application of cutting-edge technologies in brain science. Through the revolutionary TI technology, Neurodome has achieved precise deep-brain multi-target regulation in a non-invasive way, effectively breaking through the bottlenecks of existing technologies. This not only provides a powerful tool for brain science research but also brings an epoch-making innovative therapy to meet huge unmet clinical needs. Currently, Neurodome has completed the assembly of a world-class talent team and accumulated leading technology. It continues to lead the industry in clinical progress and technological iteration, demonstrating the outstanding efficacy and safety of its products in dozens of indications and hundreds of human trials. We are highly looking forward to joining hands with Neurodome to create new miracles in the field of deciphering and regulating the human brain, which holds infinite possibilities.

Dr. Ding Jingna, Vice President of iFlytek Ventures and Head of Healthcare and Life SciencesiFlytek Group has always paid close attention to the integration of brain science and artificial intelligence, as well as the opportunities for technological innovation and project implementation in this field. Neurodome possesses original foundational technology and has established an in-depth collaboration with Nir Grossman’s team, which pioneered the world's first Transcranial Electrical Stimulation (TI) non-invasive deep brain neuromodulation technology. Their technology has gained recognition from international experts. We are confident that based on this core technology, Neurodome is expected to provide more effective and convenient treatment and intervention methods for complex neurological disorders such as depression, Parkinson's disease, Alzheimer's disease, and sleep disorders through non-invasive means. We also look forward to Neurodome further integrating with artificial intelligence technologies in the future to achieve personalized and precise treatment models, becoming a leading innovative technology enterprise dedicated to safeguarding human brain health.

Feng Zhihua, President of Heying CapitalRepresentation: Brain science is a key focus area for Heying Capital. To this end, we have established the first domestic fund specifically for brain-computer interface, dedicated to discovering potential companies with revolutionary technologies. Neurodome's TI non-invasive deep brain precise neuromodulation technology is leading globally in clinical progress and product development, showing tremendous market potential in areas such as mental illness and neurodegenerative diseases. We are very optimistic about the application prospects of TI technology in the field of brain science and look forward to Neurodome's innovative products benefiting patients with brain diseases as soon as possible. We also anticipate strengthened collaboration between Neurodome and Heying Capital’s brain science ecosystem for mutual benefit, supporting the innovative development of China’s brain science sector.

Shen Yuxiao, Managing Director of Start Point AdvisorsNeurodome, as a global leader in the field of TI non-invasive deep brain neuromodulation, has reached the next significant milestone for this disruptive non-invasive modulation technology through solid technical accumulation and highly efficient clinical progress. We are honored to serve as the exclusive financial advisor to Neurodome, assisting the company in completing its Series A financing round. We look forward to Neurodome’s continued leadership and innovation in TI, providing China’s experience and innovative TI solutions to global brain science.